MX2016006270A - Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. - Google Patents

Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Info

Publication number
MX2016006270A
MX2016006270A MX2016006270A MX2016006270A MX2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A
Authority
MX
Mexico
Prior art keywords
compositions
cells
human placental
placental perfusate
subpopulations
Prior art date
Application number
MX2016006270A
Other languages
English (en)
Spanish (es)
Inventor
P Gurney Jodi
Zhang Xiaokui
Herb Stacy
J Hariri Robert
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2016006270A publication Critical patent/MX2016006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2016006270A 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. MX2016006270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
MX2016006270A true MX2016006270A (es) 2016-09-07

Family

ID=53058264

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006270A MX2016006270A (es) 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Country Status (11)

Country Link
US (2) US20160279171A1 (https=)
EP (1) EP3068432A4 (https=)
JP (4) JP2016537362A (https=)
KR (3) KR20160098244A (https=)
CN (2) CN105916521A (https=)
AU (3) AU2014348454A1 (https=)
CA (1) CA2930573C (https=)
MX (2) MX2016006270A (https=)
RU (1) RU2016123361A (https=)
WO (1) WO2015073800A2 (https=)
ZA (1) ZA201603270B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
JP2022513164A (ja) * 2018-11-30 2022-02-07 セルラリティ インク． 胎盤由来同種ｃａｒ－ｔ細胞およびその使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2432493T3 (es) * 2001-02-14 2013-12-03 Anthrogenesis Corporation Placenta de mamífero post-parto, su uso y células madre de la misma
EP2316918B1 (en) * 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2005228442A1 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory T cells and uses thereof
NZ597304A (en) * 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
WO2007087292A2 (en) * 2006-01-23 2007-08-02 Athersys, Inc. Mapc treatment of brain injuries and diseases
EP1976978A2 (en) * 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
EP4094578A1 (en) * 2006-05-11 2022-11-30 Celularity Inc. Methods for collecting and using placenta cord blood stem cells
US8562972B2 (en) 2006-10-23 2013-10-22 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CA2677679A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
CA2688504A1 (en) * 2007-06-18 2008-12-24 Children's Hospital & Research Center At Oakland Method of isolating stem and progenitor cells from placenta
KR20220122774A (ko) * 2007-09-26 2022-09-02 셀룰래리티 인코포레이티드 인간 태반 관류액으로부터의 혈관형성 세포
RU2536242C2 (ru) * 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
DK2375907T3 (da) * 2008-11-21 2019-06-11 Celularity Inc Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
EP2405912A2 (en) * 2009-03-12 2012-01-18 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2010141654A1 (en) * 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
US20120177618A1 (en) * 2009-07-14 2012-07-12 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
DK2556145T3 (en) * 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
MX342995B (es) * 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
KR20190114045A (ko) * 2010-12-17 2019-10-08 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
WO2012083023A1 (en) 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells
AR084753A1 (es) * 2010-12-30 2013-06-05 Anthrogenesis Corp Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp)
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CN114134113A (zh) 2012-08-13 2022-03-04 人类起源公司 自然杀伤细胞及其用途
DK2909314T3 (da) 2012-10-19 2021-03-08 Celularity Inc Behandling af smerte med amnion afledte vedhæftende celler

Also Published As

Publication number Publication date
ZA201603270B (en) 2022-09-28
KR20240023709A (ko) 2024-02-22
WO2015073800A3 (en) 2015-07-02
WO2015073800A2 (en) 2015-05-21
KR20210121277A (ko) 2021-10-07
JP2020019777A (ja) 2020-02-06
RU2016123361A (ru) 2017-12-20
EP3068432A4 (en) 2017-04-19
CN105916521A (zh) 2016-08-31
MX2021003799A (es) 2021-06-04
JP2016537362A (ja) 2016-12-01
AU2022215291A1 (en) 2022-09-01
US20190117705A1 (en) 2019-04-25
CA2930573C (en) 2023-12-05
WO2015073800A8 (en) 2015-12-17
US20160279171A1 (en) 2016-09-29
AU2020202182A1 (en) 2020-04-16
CN113679740A (zh) 2021-11-23
JP2024016037A (ja) 2024-02-06
EP3068432A2 (en) 2016-09-21
AU2022215291A9 (en) 2022-11-24
AU2014348454A1 (en) 2016-06-02
CA2930573A1 (en) 2015-05-21
JP2022020622A (ja) 2022-02-01
KR20160098244A (ko) 2016-08-18

Similar Documents

Publication Publication Date Title
MX2023001226A (es) Anticuerpos anti-lag-3.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PH12015502767A1 (en) Sc-� cells and compositions and methods for generating the same
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201890201A1 (ru) Антибактериальные соединения
MX2014006514A (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2024001617A (es) Composiciones biofarmaceuticas.
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
WO2016048861A3 (en) Heterocyclic compounds and use thereof
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2021003799A (es) Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.